Affiliation:
1. Merck Research Laboratories, West Point, PA 19486, USA.
2. St. Vincent's Institute of Medical Research, Melbourne 3065, Australia.
Abstract
The strength and integrity of our bones depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. As we age or as a result of disease, this delicate balancing act becomes tipped in favor of osteoclasts so that bone resorption exceeds bone formation, rendering bones brittle and prone to fracture. A better understanding of the biology of osteoclasts and osteoblasts is providing opportunities for developing therapeutics to treat diseases of bone. Drugs that inhibit the formation or activity of osteoclasts are valuable for treating osteoporosis, Paget's disease, and inflammation of bone associated with rheumatoid arthritis or periodontal disease. Far less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption.
Publisher
American Association for the Advancement of Science (AAAS)
Reference107 articles.
1. Frost H. M., Am. J. Human Biol. 10, 599 (1998);
2. Rodan G. A., Bone 20, 1 (1997).
3. Ducy P., et al., Cell 100, 197 (2000).
4. C. Cooper and L. J. Melton III in Osteoporosis R. Marcus D. Feldman J. Kelsey Eds. (Academic Press New York 1996) p. 419.
5. Jilka R. L., et al., Science 257, 88 (1992);
Cited by
1559 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献